Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide.
de la Fuente-Núñez. César C; Korolik. Victoria V; Bains. Manjeet M; Nguyen. Uyen U; Breidenstein. Elena B M EB; Horsman. Shawn S; Lewenza. Shawn S; Burrows. Lori L; Hancock. Robert E W RE
Key Findings
- Peptide 1037 (9 aa) blocks biofilm formation at ~1/30th of its minimum inhibitory concentration.
- It reduces swimming and swarming motility while increasing twitching motility in P. aeruginosa, altering genes linked to biofilm development.
- The peptide shows broad activity against Gram‑negative and Gram‑positive pathogens but has only weak direct antimicrobial killing.
Practical Outcomes
- For biohackers, the main takeaway is that tiny cationic peptides can disrupt bacterial biofilms without needing high antimicrobial doses, suggesting a potential low‑toxicity strategy for chronic infection control. However, the peptide is still experimental and not available for human use, so it currently serves more as a research insight than a DIY protocol.
Summary
Scientists found a tiny synthetic peptide (9 amino acids long) that can stop harmful bacteria from forming protective biofilms at doses far lower than needed to kill the bacteria outright. It works on several nasty bugs, including Pseudomonas, Burkholderia, and Listeria, by messing with their movement and gene activity. While it’s not a ready‑to‑use supplement, it shows that very small, positively‑charged peptides might be a new way to fight chronic infections.
Abstract
Biofilms cause up to 80% of infections and are difficult to treat due to their substantial multidrug resistance compared to their planktonic counterparts. Based on the observation that human peptide LL-37 is able to block biofilm formation at concentrations below its MIC, we screened for small peptides with antibiofilm activity and identified novel synthetic cationic peptide 1037 of only 9 amino acids in length. Peptide 1037 had very weak antimicrobial activity, but at 1/30th the MIC the peptide was able to effectively prevent biofilm formation (>50% reduction in cell biomass) by the Gram-negative pathogens Pseudomonas aeruginosa and Burkholderia cenocepacia and Gram-positive Listeria monocytogenes. Using a flow cell system and a widefield fluorescence microscope, 1037 was shown to significantly reduce biofilm formation and lead to cell death in biofilms. Microarray and follow-up studies showed that, in P. aeruginosa, 1037 directly inhibited biofilms by reducing swimming and swarming motilities, stimulating twitching motility, and suppressing the expression of a variety of genes involved in biofilm formation (e.g., PA2204). Comparison of microarray data from cells treated with peptides LL-37 and 1037 enabled the identification of 11 common P. aeruginosa genes that have a role in biofilm formation and are proposed to represent functional targets of these peptides. Peptide 1037 shows promise as a potential therapeutic agent against chronic, recurrent biofilm infections caused by a variety of bacteria.
Study Information
pubmed
2012
2012-02-21T00:00:00.000Z
10.1128/aac.00064-12